A Medicine study used artificial intelligence to discover a naturally occurring molecule, specifically, a peptide, that ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

Stanford Medicine researchers have identified a promising, naturally occurring molecule that could help people lose ...

Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...

BRP, identified through peptide prediction, may revolutionize weight loss treatment, offering efficacy without the ...

Stanford Medicine scientists have discovered a naturally occurring molecule that rivals the weight-loss effects of semaglutide-based GLP-1s in animals — without the dreaded side effects.

Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential ...

Obesity rates have more than doubled in adults and quadrupled in adolescents since 1990, making it a leading cause of ...

Stephanie Anderson Witmer is a freelance journalist based in Pennsylvania. Her work has been published in other top magazines and digital publications, including Prevention, Good Housekeeping ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone paymentsTHE WOODLANDS, Texas, ...

Novo Nordisk has entered into an exclusive license agreement with Lexicon Pharmaceuticals Inc. for LX9851, a first-in-class, ...